Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 as an Adjunctive Treatment for Residual Schizophrenia
NCT02477670Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of deudextromethorphan in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Sep 2015; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02477670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477670.